

## Mometasone Ointment Formulation

Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Mometasone Ointment Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Warning

Hazard statements : H315 Causes skin irritation.  
H319 Causes serious eye irritation.  
H361d Suspected of damaging the unborn child.

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements :

**Prevention:**

P201 Obtain special instructions before use.  
 P264 Wash skin thoroughly after handling.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
 P391 Collect spillage.

Hazardous components which must be listed on the label:

2-Methyl-2,4-pentanediol

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Methyl-2,4-pentanediol	107-41-5 203-489-0 603-053-00-3	Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d	>= 10 - < 20
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	>= 0,1 - < 0,25

For explanation of abbreviations see section 16.

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks : Causes skin irritation.  
Causes serious eye irritation.  
Suspected of damaging the unborn child.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.
- 

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

- Specific hazards during fire- : Vapours may form explosive mixtures with air.
-

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

fighting Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

**5.3 Advice for firefighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.

## Mometasone Ointment Formulation

Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
2-Methyl-2,4-pentanediol	107-41-5	OEL-RL (vapour fraction)	50 ppm	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
		OEL- RL STEL/C (vapour fraction)	100 ppm	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
		OEL- RL STEL/C (inhalable fraction, aerosol only)	20 mg/m <sup>3</sup>	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For			

# SAFETY DATA SHEET



## Mometasone Ointment Formulation



Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

	Hazardous Chemical Agents			
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Methyl-2,4-pentanediol	Workers	Inhalation	Long-term systemic effects	44,43 mg/m3
	Workers	Inhalation	Long-term local effects	49 mg/m3
	Workers	Inhalation	Acute local effects	98 mg/m3
	Workers	Skin contact	Long-term systemic effects	63 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	7,83 mg/m3
	Consumers	Inhalation	Long-term local effects	25 mg/m3
	Consumers	Inhalation	Acute local effects	49 mg/m3
	Consumers	Skin contact	Long-term systemic effects	22,5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	2,25 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food
2-Methyl-2,4-pentanediol	Fresh water	0,429 mg/l
	Freshwater - intermittent	4,29 mg/l
	Marine water	0,0429 mg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	1,59 mg/kg dry weight (d.w.)
	Marine sediment	0,159 mg/kg dry weight (d.w.)
	Soil	0,066 mg/kg dry weight (d.w.)

## 8.2 Exposure controls

### Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions,

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type (A-P)

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	: ointment
Colour	: white to off-white
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: > 93,3 °C
Evaporation rate	: No data available
Flammability (solid, gas)	: Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available

# SAFETY DATA SHEET



## Mometasone Ointment Formulation



Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

---

Solubility(ies)  
Water solubility : No data available  
Partition coefficient: n-octanol/water : No data available  
Auto-ignition temperature : No data available  
  
Decomposition temperature : No data available  
  
Viscosity  
Viscosity, kinematic : No data available  
  
Explosive properties : Not explosive  
  
Oxidizing properties : The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids) : Not applicable  
  
Molecular weight : No data available  
  
Particle size : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact



## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**Acute toxicity**

Not classified based on available information.

**Components:****2-Methyl-2,4-pentanediol:**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 420
Acute dermal toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

**Mometasone:**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg  LD50 (Mouse): > 2.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3,3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.  LC50 (Mouse): > 3,2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****2-Methyl-2,4-pentanediol:**

Result	:	Skin irritation
Remarks	:	Based on national or regional regulation.

**Mometasone:**

Species	:	Rabbit
Result	:	No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****2-Methyl-2,4-pentanediol:**

Result	:	Irritation to eyes, reversing within 21 days
Remarks	:	Based on national or regional regulation.

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**Mometasone:**

Species	: Rabbit
Result	: No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****2-Methyl-2,4-pentanediol:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative

**Mometasone:**

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Assessment	: Does not cause skin sensitisation.
Result	: negative
Remarks	: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****2-Methyl-2,4-pentanediol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Method: OECD Test Guideline 476
	Result: negative
	Test Type: Chromosome aberration test in vitro
	Result: negative

**Mometasone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosomal aberration
	Test system: Chinese hamster lung cells

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

		Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive
		Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Mometasone:**

Species	:	Rat
Application Route	:	Inhalation
Exposure time	:	2 Years
Dose	:	0.067 mg/kg body weight
Result	:	negative

Species	:	Mouse
Application Route	:	Inhalation
Exposure time	:	19 Months
Dose	:	0.160 mg/kg body weight
Result	:	negative

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****2-Methyl-2,4-pentanediol:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion
----------------------	---	---

## Mometasone Ointment Formulation

Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

		Method: OECD Test Guideline 443 Result: negative
Effects on foetal development	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 443 Result: positive
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.

**Mometasone:**

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0,015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0,06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmental toxicity
		Test Type: Embryo-foetal development Species: Rat Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0,3 mg/kg body weight Result: Embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
		Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight Result: Effects on newborn
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Embryo-foetal toxicity: LOAEL: 0,7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****2-Methyl-2,4-pentanediol:**

Species	: Rat
NOAEL	: >= 450 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

**Mometasone:**

Species	: Rat
NOAEL	: 0,005 mg/kg
LOAEL	: 0,3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
LOAEL	: 0,5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Rat
NOAEL	: 0,00013 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

## Mometasone Ointment Formulation

Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
 Date of first issue: 14.06.2017

Species : Dog  
 NOAEL : 0,0005 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 90 d  
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

|| Not applicable

**Experience with human exposure****Components:****2-Methyl-2,4-pentanediol:**

|| Eye contact : Target Organs: Eyes  
 Symptoms: Irritation

**Mometasone:**

|| Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion  
 || Skin contact : Symptoms: Dermatitis, Itching

**Further information****Components:****Mometasone:**

|| Remarks : Dermal absorption possible

**SECTION 12: Ecological information****12.1 Toxicity****Components:****2-Methyl-2,4-pentanediol:**

|| Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8.510 mg/l  
 Exposure time: 96 h  
 || Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 2.800 mg/l  
 Exposure time: 48 h  
 || Toxicity to algae/aquatic plants : ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201

## Mometasone Ointment Formulation

Version 3.0      Revision Date: 06.04.2024      SDS Number: 1751225-00016      Date of last issue: 30.09.2023  
Date of first issue: 14.06.2017

		EC10 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	NOEC (Bacteria): 200 mg/l Exposure time: 10 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 25 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
<b>Mometasone:</b>		
Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): 0,11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility  LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility  EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility  NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC: 0,00014 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,34 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
--	---	---

M-Factor (Chronic aquatic toxicity)	:	100
-------------------------------------	---	-----

**12.2 Persistence and degradability****Components:****2-Methyl-2,4-pentanediol:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 81 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---	---

**Mometasone:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
------------------	---	--

Stability in water	:	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111
--------------------	---	---

**12.3 Bioaccumulative potential****Components:****2-Methyl-2,4-pentanediol:**

Partition coefficient: n-octanol/water	:	log Pow: < 4 Remarks: Calculation
--	---	--------------------------------------

**Mometasone:**

Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107,1 Method: OECD Test Guideline 305
-----------------	---	--

Partition coefficient: n-octanol/water	:	log Pow: 4,68
--	---	---------------

**12.4 Mobility in soil****Components:****Mometasone:**

Distribution among environmental compartments	:	log Koc: 4,02
---	---	---------------



## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information****14.1 UN number**

ADN : UN 3077

ADR : UN 3077

RID : UN 3077

IMDG : UN 3077

IATA : UN 3077

**14.2 UN proper shipping name**

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

(Mometasone)

**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Mometasone)

**IATA** : Environmentally hazardous substance, solid, n.o.s.  
(Mometasone)

**14.3 Transport hazard class(es)**

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

**14.4 Packing group**

**ADN**

Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**ADR**

Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**

Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**IMDG**

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

**IATA (Cargo)**

Packing instruction (cargo aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

**IATA (Passenger)**

Packing instruction (passenger aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**14.5 Environmental hazards****ADN**

Environmentally hazardous : yes

**ADR**

Environmentally hazardous : yes

**RID**

Environmentally hazardous : yes

**IMDG**

Marine pollutant : yes

**IATA (Passenger)**

Environmentally hazardous : yes

**IATA (Cargo)**

Environmentally hazardous : yes

**14.6 Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H315 : Causes skin irritation.

H319 : Causes serious eye irritation.

H360Df : May damage the unborn child. Suspected of damaging fertility.

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

H361d : Suspected of damaging the unborn child.  
H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.  
H410 : Very toxic to aquatic life with long lasting effects.

**Full text of other abbreviations**

Aquatic Chronic : Long-term (chronic) aquatic hazard  
Eye Irrit. : Eye irritation  
Repr. : Reproductive toxicity  
Skin Irrit. : Skin irritation  
STOT RE : Specific target organ toxicity - repeated exposure  
ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits  
ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)  
ZA OEL / OEL- RL STEL/C : Occupational Exposure Limit Restricted limit - Short term occupational exposure limits / ceiling limits

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

## Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.0	06.04.2024	1751225-00016	Date of first issue: 14.06.2017

---

**Classification of the mixture:**

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Repr. 2	H361d
Aquatic Chronic 2	H411

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN